StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
BMO Capital Upgrades Biogen (BIIB) to Outperform
October 25, 2017 1:01 AM
BMO Capital upgraded Biogen (NASDAQ: BIIB) from Market Perform to Outperform with a price target of $381.00 (from $382.00).Analyst Ian ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Upgrades
Next Articles
Biogen (BIIB) PT Raised to $355 at Leerink Partners
October 25, 2017 7:29 AM
Biogen (BIIB) Reports AFFINITY Phase 2 Trial Initiation for Opicinumab (Anti-LINGO-1) in Multiple Sclerosis
October 25, 2017 5:56 AM
Biogen (BIIB) Weakness Is Buying Opportunity - Goldman Sachs
October 24, 2017 2:35 PM
SPINRAZA Confusion Creates a Buying Opportunity in Biogen (BIIB) - Stifel
October 24, 2017 11:58 AM
Biogen (BIIB) Tops Q3 EPS by 61c
October 24, 2017 7:00 AM
Guggenheim Starts Biogen (BIIB) at Buy
October 23, 2017 4:20 PM
Biogen (BIIB) PT Raised to $430 at Stifel
October 23, 2017 11:53 AM
